This webinar covered
Of the 1902 assets currently captured on Beacon Gene Therapy, nearly 60% leverage AAV’s. With this choice, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be. Join us online to be part of the solution to bringing safer, effective genetic therapies to patients and gain immediately implementable data insights to sharpen your programs currently in development.
This webinar will uncover analysis on:
- Preclinical models leveraged to assess safety of viral vectors
- Immunogenicity information from historic and ongoing trials
- Insights into the reason for recent clinical holds in the viral delivery space